Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906434 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
A Phase 1 study of Advanced Liver Cancer, sponsored by Abbisko Therapeutics Co.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT04906434 is a Phase 1 study of Advanced Liver Cancer that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 200 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT04906434, a Phase 1 study of Advanced Liver Cancer, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label phase 1 study with an escalation part and an expansion part.
Conditions Studied
Interventions
- DRUG ABSK-011
Study Locations (20)
Florida
- Mayo Clinic - Jacksonville
- Moffitt Cancer Center - Tampa
Beijing Municipality
- Beijing Tsinghua Changgung Hospital - Beijing
- The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army - Beijing
Henan
- First Affiliated Hospital of Henan University of Science and Technology - Luoyang
- Henan Cancer Hospital - Zhengzhou
Hubei
- Hubei Cancer Hospital - Wuhan
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology - Wuhan
Arizona
- Mayo Clinic - Phoenix
Minnesota
- Mayo Clinic - Rochester
New York
- Icahn School of Medicine at Mount Sinai - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906434
The ClinicalTrials.gov registry entry for NCT04906434 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbisko Therapeutics Co, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABSK-011 is the first listed.
NCT04906434 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Beijing Municipality, Henan.
Frequently Asked Questions
What is clinical trial NCT04906434 about?
NCT04906434 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor". This is an open-label phase 1 study with an escalation part and an expansion part.
What is the current status of trial NCT04906434?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2020-02-26. Estimated completion is 2028-12-31.
What conditions does trial NCT04906434 study?
This clinical trial studies the following conditions: Advanced Liver Cancer.
What interventions are being tested in trial NCT04906434?
The interventions under investigation include: ABSK-011 (DRUG).
Who is sponsoring clinical trial NCT04906434?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906434 being conducted?
This trial has 20 study locations across Arizona, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.